EAHAD 2026 at a Glance
Get ready for EAHAD 2026. LucidQuest’s preview highlights the most relevant scientific and AI-driven developments in hemophilia and rare bleeding disorders, helping you focus on high-impact sessions and plan a smart, insight-driven agenda.
đź“… Build your schedule around the topics that matter most.
đź“Ą Download the EAHAD 2026_Preview_by_LucidQuest
Dive deeper
Key Topics from EAHAD 2026 Scientific Presentations
Emicizumab and Real-World Prophylaxis Optimization
- Pediatric real-world data point to lower annualized bleeding rates, improved joint health on MRI, and opportunities for dose optimization, supporting more cost-effective long-term prophylaxis strategies.
Gene Therapy, RNA, and Novel Molecular Therapeutics
- Long-term follow-ups from HOPE-B and GENEr8-1 are expected to reinforce sustained bleed reduction, stable factor activity, and ongoing evaluation of liver safety in hemophilia A and B.
Factor Replacement Therapies, PK, and Long-Term Outcomes
- XTEND-ed supports the durability of once-weekly efanesoctocog alfa, while Alfa-PROTECT confirms the safety and low bleeding rates of damoctocog alfa pegol, including in pediatric populations.
Non-Factor Therapies and Antibody-Based Approaches
- Marstacimab demonstrates approximately ninety-three percent joint-bleed reduction in patients with inhibitors, with strong control at target joints. Concizumab continues to position itself as a once-daily option across hemophilia A and B.
Von Willebrand Disease and Rare Coagulation Disorders
- WIL-33 highlights the role of pdVWF/FVIII prophylaxis in young children, while PopPK-WILPROPHY emphasizes personalized dosing approaches to reduce bleeds and preserve quality of life.
Clinical Management, Adherence, QoL, and Health Systems
- Advanced monitoring tools are increasingly linking prophylaxis adherence with joint protection, functional outcomes, and predictive care planning, bringing psychosocial and health-system factors into routine management.
Artificial Intelligence and Machine Learning at EAHAD 2026
Generative AI for Hemophilia Management
- Clinician-supervised AI copilots are emerging to support diagnosis, treatment planning, and safer optimization of gene therapy protocols.
AI in Social Listening for Hemophilia
- AI models are being applied to social media analysis to identify activity limitations, stigma signals, and unmet needs—informing more integrated clinical and social support strategies.
AI-Driven Insights into Physician Perspectives
- Natural language processing is being used to capture physician preferences around rebalancing agents, balancing convenience, patient-centered care, and efficacy.
AI for Standardization in Fibrinolysis Diagnostics
- AI-assisted interpretation aims to harmonize fibrinolysis assays, improving cross-laboratory consistency and protocol alignment across Europe.
AI Integration in Genetic Testing for Platelet Disorders
- New tools combine genetic variants with functional platelet assays, strengthening pathogenicity assessment in conditions such as Hermansky–Pudlak syndrome.
đź“… Build your schedule around the topics that interest you.
đź“Ą Download the EAHAD 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.